Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics, Inc. (KYMR) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 18.76 M | -25,292,000 | 180.79 M | 575.76 M | 405.32 M |
| 2022 | 2.54 M | -51,060,000 | 112.98 M | 603.13 M | 559.49 M |
| 2021 | 135 K | -30,013,000 | 146.27 M | 605.91 M | 567.61 M |
| 2020 | 1.43 M | -13,011,000 | 203.29 M | 487.18 M | 302.34 M |
| 2019 | -54,822,000 | 191.11 M | 116.7 M | 92.85 M |